



PHARMACEUTICAL 2022











RealRate

PHARMACEUTICAL 2022



RAPT Therapeutics Inc. Rank 93 of 466

The relative strengths and weaknesses of RAPT Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RAPT Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 67% points. The greatest weakness of RAPT Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 238%, being 160% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	192,973
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,595
Liabilities, Non-Current	0
Other Assets	2,922
Other Compr. Net Income	-29
Other Expenses	0
Other Liabilities	2,661
Other Net Income	5.0
Other Revenues	3,813
Property and Equipment	2,741
Research and Development	56,985
Selling, General and Administrative Expense	16,037

Output Variable	Value in 1000 USD
Assets	198,636
Liabilities	12,256
Expenses	73,022
Revenues	3,813
Stockholders Equity	186,380
Net Income	-69,204
Comprehensive Net Income	-69,218
Economic Capital Ratio	238%

